Patents Examined by Lisa Cook
  • Fibrinogen assay
    Patent number: 8900822
    Abstract: The present invention is directed to a method of detecting intact fibrinogen, comprising the steps of: a) providing a sample containing at least some fibrinogen optionally converted at least in part to fibrin, and optionally containing thrombin; b) solubilizing the sample in a solubilizing solution that inhibits thrombin activity; c) after optional SDS-PAGE transferring/applying a portion of said sample to a protein-binding membrane; d) reacting the fibrinogen with a primary monoclonal antibody capable of binding to fibrinopeptide A moiety; and e) detecting the quantity of intact fibrinogen in the sample by quantifying the amount of the bound primary monoclonal antibody.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: December 2, 2014
    Assignee: Ethicon, Inc.
    Inventors: Ashley DeAnglis, Elif Burcoglu
  • Marker for graft failure and mortality
    Patent number: 8889366
    Abstract: Subject of the present invention is a biomarker for graft failure and/or mortality after organ transplantation. Procalcitonin was found to be a useful marker for the prediction or risk stratification for graft failure and/or mortality of a subject who has received an organ transplant and monitoring and therapy guidance of such subject.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: November 18, 2014
    Assignee: B.R.A.H.M.S. GmbH
    Inventors: Joachim Struck, Stephanus Johannes Bakker
  • Biomarkers and methods for determining disease progression in nonalcoholic steatohepatitis (NASH)
    Patent number: 8871454
    Abstract: Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans. Provided herein are biomarkers, methods, and animal models useful for the investigation and non-invasive detection of NASH, including a non-invasive biomarker that could be used to establish disease severity, follow progression, and evaluate response to treatment in clinical trials for this increasingly prevalent disease.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: October 28, 2014
    Assignee: Children's Hospital Medical Center
    Inventors: Rohit Kohli, Stavra A. Xanthakos, Michael V. Miles
  • Diagnosis of preeclampsia
    Patent number: 8871448
    Abstract: The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: October 28, 2014
    Assignee: Yale University
    Inventors: Catalin S. Buhimschi, Irina Buhimschi, Errol Norwitz
  • Immunoanalytical method and system using mass spectrometry technology
    Patent number: 8865418
    Abstract: An immunoanalytical system in which, after a sample such as a patient's serum is subjected to a pretreatment by an immunological pretreatment device, the sample is subjected to light detection by an immunological photometric detection system. Subsequently, the mass spectrometric pretreatment device performs a pretreatment, and the mass spectrometric detection system performs mass spectrometry. The mass spectrometric detection system performs mass spectrometry on components contained in a supernatant. A signal intensity and peak area for each of components are calculated from an obtained chromatograph. A quantitative value measured based on the immunoanalytical method is calculated for each of the components on the basis of the relative ratios of the components.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: October 21, 2014
    Assignee: Hitachi High-Technologies Corporation
    Inventors: Katsuhiro Kanda, Makoto Nogami, Izumi Waki
  • PAS kinase assays
    Patent number: 8859214
    Abstract: The present invention is directed towards methods for measuring and assaying PAS Kinase activity. The methods are useful, for example, for detecting PASK activity in a cell, and for screening for small molecule regulators of PAS kinase activity, as well as characterizing endogenous factors and stimuli that modulate PAS kinase activity, and identifying and optimizing the activity of potential PAS kinase inhibitors.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: October 14, 2014
    Assignee: University of Utah
    Inventors: Jared Rutter, Wojciech Swiatek
  • Cell binding assay
    Patent number: 8859215
    Abstract: The present invention relates to a fluorescent cell binding assay combining pre-labeling and Western blotting. Intact cells are incubated with pre-labelled binders preferably followed by SDS PAGE (sodium dodecylsulphate polyacrylamide gel) separation and Western blotting. More closely, the invention relates to a cell binding assay in which the degree or amount of binding of one or more cell interacting protein or protein component to the cell surface is measured with the ability to correlate the degree of cell binding to the sample load/total number of cells.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: October 14, 2014
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Susanne Grimsby, Asa Hagner-McWhirter
  • Method for noninvasive prediction or diagnosis of inflammation and infection in amniotic fluid of patients with premature rupture of membranes
    Patent number: 8859216
    Abstract: Provided is a method for noninvasive prediction or diagnosis of inflammation and/or infection in amniotic fluid leaked through the cervix into the vagina to predict the concentration of inflammatory markers in the amniotic fluid inside uterus by measuring the concentration of inflammatory markers (various cytokines). Further provided is a method for prediction or diagnosis of inflammation and/or infection in amniotic fluid by measuring the concentration of markers (IL-6, IL-1? IL-8, MCP-1, GRO-?) in the amniotic fluid leaked through the cervix into the vagina in patients with premature rupture of membranes. The method can be performed more stably on pregnant women, as compared to the conventional method for prediction or diagnosis of inflammation and/or infection using invasively collected amniotic fluid.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: October 14, 2014
    Assignees: Snu R&DB Foundation, Ob Med
    Inventors: Bo Hyun Yoon, Joong Shin Park, Jong Kwan Jun, Chan Wook Park
  • Apparatus and method for identifying a hook effect and expanding the dynamic range in point of care immunoassays
    Patent number: 8852877
    Abstract: The present invention relates to systems and methods for the rapid in situ determination of the existence of a hook effect and expansion of the dynamic range of a point of care immunoassay. For example, a system for identifying a hook effect and expanding the dynamic range of an immunoassay is provided that may include a primary sensor having first immobilized antibodies that may be configured to generate a first signal based on a presence or absence of a target analyte in a sample. The system may further include an attenuated sensor having second immobilized antibodies at a reduced concentration relative to a concentration of the first immobilized antibodies on the primary sensor and that may be configured to generate a second signal based on the presence or absence of the target analyte in the sample.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: October 7, 2014
    Assignee: Abbott Point of Care Inc.
    Inventors: John Campbell, Linda Nguyen, James Smith, Wenda Weiss
  • Methods and system for the automated determination of immunofluorescent foci using a cell-based immunofluorescence assay using synthetic calibration particles
    Patent number: 8835122
    Abstract: The invention relates to a method for automated determination of immunofluorescent foci by means of an immunofluorescence assay using synthetic calibration particles, in addition to a system and kit for carrying out the method. In a preferred embodiment the method is characterized in that the immunofluorescent foci are gamma H2Ax foci.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: September 16, 2014
    Assignees: Medipan GmbH
    Inventor: Dirk Roggenbuck
  • Cobalamin assay
    Patent number: 8802382
    Abstract: The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: August 12, 2014
    Assignee: Axis-Shield ASA
    Inventors: Lars Orning, Anne Rian
  • Method for testing or screening protein synthesis inhibitors
    Patent number: 8802380
    Abstract: This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: August 12, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Mumtaz Kasim
  • Methods for predicting pregnancy outcome in a subject by HCG assay
    Patent number: 8802381
    Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: August 12, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: John O'Connor, Steven Birken, Galina Kovalevskaya
  • Methods and compositions for diagnosis and risk prediction in heart failure
    Patent number: 8795975
    Abstract: The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.
    Type: Grant
    Filed: November 25, 2011
    Date of Patent: August 5, 2014
    Assignee: Alere San Diego, Inc.
    Inventors: William D. Arnold, Christelle Jost, Brian Noland, Jonathan Gary, Joseph Buechler, Vance Wong, Scott Harold Rongey, Uday Kumar Veeramallu, Kelline Marie Rodems
  • Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
    Patent number: 8790882
    Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: July 29, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maher Albitar, Michael J. Keating, Taghi Manshouri
  • Modification-dependent activity assays
    Patent number: 8785139
    Abstract: Disclosed herein are methods, systems and kits to measure the presence and/or activity of recombinant polypeptides comprising a modification.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: July 22, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Alfred Weber, Andrea Engelmaier, Hans-Peter Schwarz
  • Biomarker for osteoarthritis and/or other ageing-related diseases, and use thereof
    Patent number: 8771968
    Abstract: The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: July 8, 2014
    Assignee: Universitè de Liège
    Inventors: Yves Henrotin, Myriam Gharbi, Michelle Deberg, Edwin De Pauw
  • Peptide antibody depletion and its application to mass spectrometry sample preparation
    Patent number: 8771969
    Abstract: The present invention relates, e.g., to a method for pre-processing a sample for mass spectral analysis, comprising cleaving proteins in the sample to peptides and immunodepleting highly abundant and/or well-ionizing and/or proteotypic peptides from the sample. Also described are methods for identifying well-ionizing peptides for use in this and other methods; analytic (diagnostic) methods using antibodies against highly ionizable peptides from a protein target of interest; and compositions, kits and devices comprising antibodies of the invention.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: July 8, 2014
    Assignee: The Johns Hopkins University
    Inventors: Jennifer E. Van Eyk, David Raymond Graham, Rebekah Lynn Gunrdy
  • Electronic methods for the detection of analytes
    Patent number: 8741585
    Abstract: The present invention is directed to the detection of target analytes using electronic techniques, particularly AC techniques.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: June 3, 2014
    Assignee: Clinical Micro Sensors, Inc.
    Inventors: Stephen D. O'Connor, Jon Faiz Kayyem, Thomas J. Meade
  • Methods and kit for endometriosis screening
    Patent number: 8722349
    Abstract: Methods of screening a bodily sample for endometriosis are provided. The bodily sample is preferably saliva. According to one embodied method, the bodily sample is subjected to a denaturing procedure, and a property of the bodily sample observed after the denaturing procedure is evaluated for the presence or absence of a factor correlating to endometriosis as part of an endometriosis screening procedure. The methods embodied herein are preferably conducted in combinations which permit for the evaluation of at least two different physiological factors correlating to endometriosis, because women with endometriosis do not always share the same factors. Also provided are screening kits, assay methods, and systems for endometriosis screening.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: May 13, 2014
    Assignee: Oratel Diagnostics, LLC
    Inventor: Dorothee Goldman